Medtronic delivered a stronger-than-expected first quarter, beating EPS and revenue forecasts and lifting FY27 adjusted EPS guidance. The company also disclosed a $700 million strategic partnership with Cornerstone Robotics to broaden Sentire Surgical System access in select non-U.S. markets. This earnings beat combined with international expansion may support near-term multiple expansion and longer-term growth.
Medtronic delivered a strong Q1 FY27, with revenue of $9.756B and 13.7% organic growth, prompting a raised FY27 target of 7.25–7.75% and EPS guidance of $5.94–$6.00. Growth was broad-based across cardiovascular, neuroscience, and medical-surgical platforms, complemented by new growth initiatives (Affera CE Mark expansion, Sphere-9 catheter) and strategic bets in robotics and leaflet technology, signaling durable upside into 2027 and beyond.
Medtronic posted an earnings beat with adjusted EPS of $1.55 and revenue of $9.81B, up 9.9%. Cardiovascular sales rose 13.8% YoY to $3.80B, bolstering growth momentum. BTIG upgraded MDT to Buy with a $90 target, while Leerink trimmed its forecast to $104, signaling near-term upside amid improving organic growth.
Medtronic delivered strong Q4 and full-year 2026 results, beating revenue and earnings expectations. Growth was driven by cardiac ablation, diabetes, and medical-surgical products, with management signaling ongoing strategic acquisitions and portfolio expansions to sustain a multi-year expansion trajectory. The company cited growth momentum and potential margin resilience.
Medtronic beat Q4 revenue and adjusted earnings estimates, driven by steady demand for its heart devices used in complex cardiac procedures. The result signals resilience in the cardiovascular device market and could drive near-term stock activity, though the article provides no numeric details or updated guidance. Investors will watch for any new outlook in subsequent releases.
Medtronic is set to acquire SPR Therapeutics for about $650 million, which will enhance its neuromodulation portfolio by integrating temporary PNS technology. This move aims to bolster Medtronic's capacity to provide earlier interventions for chronic pain management, a significant market with about 50 million U.S. adults affected, potentially driving growth in revenue and market share in the pain management segment.
